Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
10:51am, Tuesday, 11'th Nov 2025
Revolution Medicines, Inc. ( RVMD ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conf
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
03:01pm, Thursday, 06'th Nov 2025
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
Nisa Investment Advisors LLC Sells 1,221 Shares of Revolution Medicines, Inc. $RVMD
03:52am, Thursday, 06'th Nov 2025
Nisa Investment Advisors LLC cut its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 38.0% during the second quarter, according to the company in its most recent disclosure with the
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript
08:41pm, Wednesday, 05'th Nov 2025
Revolution Medicines, Inc. ( RVMD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, President & Cha
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
04:02pm, Wednesday, 05'th Nov 2025
Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has i
Revolution Medicines to Participate in November 2025 Investor Conferences
04:05pm, Tuesday, 04'th Nov 2025
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
04:05pm, Wednesday, 29'th Oct 2025
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
08:00pm, Thursday, 16'th Oct 2025
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
09:00am, Monday, 29'th Sep 2025
REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug
02:14pm, Thursday, 11'th Sep 2025
Revolution Medicines, Inc. RVMD stock is trading higher after the company shared updates from its Daraxonrasib Phase 1 trials on Wednesday.
Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold
01:30pm, Thursday, 11'th Sep 2025
Revolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer, showing high response and disease control rates. Daraxonrasib demonstrated superior ef
Revolution Medicines, Inc. (RVMD) Discussion On Metastatic Pancreatic Cancer Update Call (Transcript)
08:44am, Thursday, 11'th Sep 2025
Revolution Medicines, Inc. Metastatic Pancreatic Cancer Update Call September 10, 2025 5:00 PM EDT Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, Pre
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability
